For example, when combined mogamulizumab, an anti-CCR4 antibody, and nivolumab in patients with advanced solid tumors, four out of 15 hepatocellular carcinoma patients (27%) had confirmed tumor responses, one out of 15 pancreatic cancer patients had confirmed response and two out of 15 pancreatic adenocarcinoma patients had unconfirmed responses. This evidence concerns the gene CCR4 and neoplasm.